---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-036492"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-05-19T20:30:03+00:00"
generated_at: "2026-05-19T21:00:55.123015+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vistagen appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026

## Summary
- Dr. Angelov brings two decades of industry experience including roles at Karuna Therapeutics, Neurocrine Biosciences, Novartis, and Teva.
- Annual base salary of $425,000, $50,000 signing bonus paid in two tranches, and eligibility for annual discretionary bonus (target 45% of salary).
- Inducement grant of 150,000 stock options at $0.5955 per share, vesting over 4 years with 25% cliff at one year.
- Dr. Angelov is board-certified in psychiatry and holds an MBA from Wharton; will lead clinical development for Vistagen's pherine pipeline.

## SEC filing metadata
- accession: 0001628280-26-036492
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-05-19T20:30:03+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/0001628280-26-036492-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/vtgn-20260518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-036492
- JSON: https://secwatch.observer/filing/0001628280-26-036492.json
- Plain text: https://secwatch.observer/filing/0001628280-26-036492.txt

## Key facts
- Executive change
  Angel S. Angelov, M.D., MBA was appointed as Chief Medical Officer at Vistagen Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/0001628280-26-036492-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.